Biostar Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, the company reported net sales of $644,933 compared to $4,206,550 a year ago. Loss from operations was $1,961,999 compared to $1,701,019 a year ago. Loss before income taxes was $1,563,671 compared to $1,244,694 a year ago. Net loss was $1,563,671 or $0.71 per diluted share compared to $1,254,753 or $0.57 per diluted share a year ago. For nine months, the company reported net sales of $2,066,698 compared to $25,291,531 a year ago. Loss from operations was $9,490,821 compared to $3,664,201 a year ago. Loss before income taxes was $9,086,460 compared to $2,545,168 a year ago. Net loss was $9,086,460 or $4.11 per diluted share compared to $1,907,284 or $0.86 per diluted share a year ago. Net cash provided by operating activities was $911,057 compared to net cash used in operating activities were of $206,821 a year ago.